Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31243807 | 1.00 | ENPP2 (0.52) | ENPP2CA1CA2TUBB4ATUBB | |
| SCHEMBL8830 | 0.84 | ENPP2 (0.61) | ENPP2CA1CA2TUBB4ATUBB | |
| SCHEMBL22960752 | 0.81 | ENPP2 (0.36) | ENPP2CA1CA2TUBB4ATUBB | |
| SCHEMBL1979081 | 0.79 | FGFR1 (0.41) | ENPP2ALDH1A1CYP3A4 | |
| SCHEMBL29955032 | 0.79 | KAT6A (0.36) | ENPP2CA1CA2ALDH1A1 | |
| SCHEMBL16052743 | 0.79 | ENPP2 (0.35) | ENPP2CA1CA2 | |
| SCHEMBL7703491 | 0.79 | KAT6A (0.36) | ENPP2CA1CA2ALDH1A1 | |
| SCHEMBL18861328 | 0.77 | ENPP2 (0.53) | ENPP2CA1CA2TUBB4ATUBB | |
| SCHEMBL2842208 | 0.77 | ENPP2 (0.53) | ENPP2CA1CA2TUBB4ATUBB | |
| SCHEMBL168353 | 0.77 | ALDH1A1 (0.69) | CA1CA2TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777153-A | 20 (S) -10, 11-difluoro methylenedioxy camptothecine derivative and preparation method and application thereof | 浙江工业大学 | 2024-03-29 | — | — | CN | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4116302-B1 | COMPOUND AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN PREPARATION OF THERAPEUTIC ANTI-CANCER DRUG | TIANJIN JIKUN MEDICAL TECH CO LTD (CN) | 2025-10-29 | — | — | EP | disclosed |
| EP-4619386-A1 | ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-22 | — | — | US | disclosed |
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2025-03-27 | — | — | US | disclosed |
| WO-2025011533-A1 | CARBOXYLIC ACID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海宇道生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-4480477-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | Kanaph Therapeutics Inc. (KR) | 2024-12-25 | — | — | EP | disclosed |
| US-6903215-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1490062-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1490317-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003082280-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082787-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | ENPP2 2112/4885CA1 4788/4885CA2 4028/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | ENPP2 1006/4885CA1 2762/4885CA2 2217/4885 |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | PTGES2, PTGIR, PTGES | ENPP2 848/4885CA1 3514/4885CA2 1475/4885 |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | ENPP2 415/4885CA1 1225/4885CA2 1041/4885 |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | ENPP2 400/4885CA1 1592/4885CA2 1346/4885 |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | ENPP2 415/4885CA1 1225/4885CA2 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.